<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.106152</article-id><article-id pub-id-type="publisher-id">ACM-36158</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200600000_19572258.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  CD4
  <sup>+</sup> T淋巴细胞计数与狼疮肾炎疾病活动度的相关性研究
  Correlation Analysis of CD4
  <sup>+</sup> T Cell Count with Disease Activity in Patients with Lupus Nephritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>媛媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>焕焕</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>丽芹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>磊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钟</surname><given-names>艳艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>余杭区第一人民医院风湿内分泌科，浙江 杭州</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院风湿免疫科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>06</issue><fpage>1004</fpage><lpage>1010</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨不同疾病活动度的狼疮肾炎(Lupus nephritis, LN)患者血液CD4
   <sup>+</sup> T细胞计数与LN患者疾病活动度的相关性。方法：收集2017年10月至2019年3月在青岛大学附属医院风湿免疫科169例狼疮肾炎(LN)患者临床资料，按照SLE活动指数(systemic lupus erythematosus disease activity index, SLEDAI)分为病情活动组(n = 77)和病情稳定组(n = 92)，对照组为同期确诊为SLE且病情稳定的非LN患者(n = 64)。对CD4
   <sup>+</sup> T细胞计数与SLEDAI评分、实验室指标的相关性进行统计学分析。结果：病情活动组CD4
   <sup>+</sup> T细胞计数平均值低于病情稳定组[(227.46 &#177; 104.34)和(348.91 &#177; 98.22) cells/μl, P &lt; 0.01]；同时低于对照组[(378.88 &#177; 169.61) cells/μL, (P &lt; 0.01)]。对照组、病情稳定组、病情活动组的CD4
   <sup>+</sup> T细胞计数与SLEDAI评分呈负相关(r = −0.445, P = 0.038; r = −0.419, P = 0.022; r = −0.673, P = 0.001)，病情稳定组与病情活动组CD4
   <sup>+</sup> T细胞计数与24小时蛋白尿定量负相关(r = −0.544, P = 0.041; r = −0.629, P = 0.032)。结论：高疾病活动度的LN患者CD4
   <sup>+</sup> T细胞计数明显降低，并与24小时蛋白尿定量负相关，提示临床中可通过监测CD4
   <sup>+</sup> T细胞计数的动态改变判断LN病情活动，指导LN的临床治疗。
    Objection: To analyze the changes of serum CD4
   <sup>+</sup> T cell count in lupus nephritis (LN) patients with different disease activities, and to investigate the correlation between CD4
   <sup>+</sup> T cell count and clinical manifestations, laboratory examination and disease activity. Methods: A total of 169 patients with LN were divided into active group (n = 77) and stable group (n = 92) according to SLEDAI score. The CD4
   <sup>+</sup> T cell count and the correlation between CD4
   <sup>+</sup> T cell count and SLEDAI score was analyzed among the three groups, as well as analyzed the correlation between the CD4
   <sup>+</sup> T cell count and laboratory indexes. Results: 1) The average count of CD4
   <sup>+</sup> T cell in active groups was significantly lower than stable group [(227.46 &#177; 104.34) vs (348.91 &#177; 98.22) cells/μl, P&lt;0.01], and lower than that in control group [(378.88 &#177; 169.61) cells/μl, (P &lt; 0.01)]; 2) The CD4
   <sup>+</sup> T cell count of all the groups had significant negative correlation with SLEDAI score (r = −0.445, P = 0.038; r = −0.419, P = 0.022; r = −0.673, P = 0.001); 3) The CD4
   <sup>+</sup> T cell count of active group and stable group had a significant negative correlation with 24 hours urinary protein excretion (r = −0.544, P = 0.041; r = −0.629, P = 0.032). Conclusion: The CD4
   <sup>+</sup> T cell count in LN Patients with high disease activity was significantly decreased and negatively correlated with 24-hour albuminuria. Our study suggests that the disease activity of LN can be assessed by monitoring the change of CD4
   <sup>+</sup> T cell count, thus benefit the clinical treatment of LN. 
  
 
</p></abstract><kwd-group><kwd>系统性红斑狼疮，CD4<sup>+</sup> T细胞，狼疮肾炎，SLEDAI, Systemic Lupus Erythematosus</kwd><kwd> CD4<sup>+</sup> T Cell</kwd><kwd> Lupus Nephritis</kwd><kwd> SLEDAI</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>CD4<sup>+</sup> T淋巴细胞计数与狼疮肾炎疾病活动度的相关性研究</title><p>张媛媛<sup>1</sup>，董静<sup>1*</sup>，马焕焕<sup>2</sup>，王丽芹<sup>1</sup>，赵磊<sup>1</sup>，潘琳<sup>1</sup>，钟艳艳<sup>1</sup></p><p><sup>1</sup>青岛大学附属医院风湿免疫科，山东 青岛</p><p><sup>2</sup>余杭区第一人民医院风湿内分泌科，浙江 杭州</p><disp-formula id="hanspub.36158-formula31"><graphic xlink:href="//html.hanspub.org/file/22-1571332x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年5月25日；录用日期：2020年6月11日；发布日期：2020年6月18日</p><disp-formula id="hanspub.36158-formula32"><graphic xlink:href="//html.hanspub.org/file/22-1571332x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨不同疾病活动度的狼疮肾炎(Lupus nephritis, LN)患者血液CD4<sup>+</sup> T细胞计数与LN患者疾病活动度的相关性。方法：收集2017年10月至2019年3月在青岛大学附属医院风湿免疫科169例狼疮肾炎(LN)患者临床资料，按照SLE活动指数(systemic lupus erythematosus disease activity index, SLEDAI)分为病情活动组(n = 77)和病情稳定组(n = 92)，对照组为同期确诊为SLE且病情稳定的非LN患者(n = 64)。对CD4<sup>+</sup> T细胞计数与SLEDAI评分、实验室指标的相关性进行统计学分析。结果：病情活动组CD4<sup>+</sup> T细胞计数平均值低于病情稳定组[(227.46 &#177; 104.34)和(348.91 &#177; 98.22) cells/μl, P &lt; 0.01]；同时低于对照组[(378.88 &#177; 169.61) cells/μL, (P &lt; 0.01)]。对照组、病情稳定组、病情活动组的CD4<sup>+</sup> T细胞计数与SLEDAI评分呈负相关(r = −0.445, P = 0.038; r = −0.419, P = 0.022; r = −0.673, P = 0.001)，病情稳定组与病情活动组CD4<sup>+</sup> T细胞计数与24小时蛋白尿定量负相关(r = −0.544, P = 0.041; r = −0.629, P = 0.032)。结论：高疾病活动度的LN患者CD4<sup>+</sup> T细胞计数明显降低，并与24小时蛋白尿定量负相关，提示临床中可通过监测CD4<sup>+</sup> T细胞计数的动态改变判断LN病情活动，指导LN的临床治疗。</p><p>关键词 :系统性红斑狼疮，CD4<sup>+</sup> T细胞，狼疮肾炎，SLEDAI</p><disp-formula id="hanspub.36158-formula33"><graphic xlink:href="//html.hanspub.org/file/22-1571332x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1571332x8_hanspub.png" /> <img src="//html.hanspub.org/file/22-1571332x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>系统性红斑狼疮(Systemic Lupus erythematosus, SLE)是一种慢性自身免疫性疾病，以复杂病理机制及累及全身多脏器导致多样临床表现为主要特点，狼疮肾炎(Lupus nephritis, LN)是系统性红斑狼疮患者临床表现中最为常见的并发症，其病情活动性及治疗效果直接决定了狼疮患者的生活预后 [<xref ref-type="bibr" rid="hanspub.36158-ref1">1</xref>]。狼疮肾炎发病机制尚未完全明确，已有研究表明，CD4<sup>+</sup> T细胞在狼疮肾炎的疾病发展过程中承担着重要的角色 [<xref ref-type="bibr" rid="hanspub.36158-ref2">2</xref>]。但关于CD4<sup>+</sup> T细胞计数与狼疮肾炎的疾病活动性是否相关以及对临床是否有指导意义，相关研究报道较少。因此，本研究旨在研究不同疾病活动度的狼疮肾炎患者血液CD4<sup>+</sup> T细胞绝对计数的变化，探讨CD4<sup>+</sup> T细胞计数与实验室检查及疾病活动度的相关性，从而指导LN的治疗。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 研究对象及分组</title><p>选取2017年10月至2019年3月在青岛大学附属医院风湿免疫科诊断为LN患者共169例。根据SLEDAI评分 [<xref ref-type="bibr" rid="hanspub.36158-ref3">3</xref>] 分为病情稳定组(SLEDAI &lt; 10)，病情活动组(SLEDAI ≥ 10)。本研究已通过青岛大学附属医院伦理委员会审批。</p><sec id="s4_1_1"><title>2.1.1. 纳入标准</title><p>符合2012年系统性红斑狼疮国际合作组织(SLICC)修订的美国风湿病学会(ACR)修订的SLE诊断标准 [<xref ref-type="bibr" rid="hanspub.36158-ref4">4</xref>]，LN的判断标准符合以下标准中至少一项：1) 具有血尿临床表现，尿液检测示红细胞&gt;3个HP，或管型尿；2) 尿蛋白(+++)、24小时尿蛋白定量≥0.5 g；3) 行肾穿刺活检明确诊断为狼疮肾炎；4) 排除泌尿系统自身病变及其他原因导致的肾功能不全。</p><p>对照组：同期选取门诊接受正规治疗，尿蛋白阴性且病情稳定6个月以上，且未使用免疫抑制及免疫增强剂的非LN的SLE患者。</p></sec><sec id="s4_1_2"><title>2.1.2. 排除标准</title><p>所纳入的3组研究对象均同时排除感染、消化系统疾病、内分泌系统疾病、血液系统肿瘤、妊娠、恶性肿瘤病史、及其他自身免疫性疾病的患者。</p></sec></sec><sec id="s4_2"><title>2.2. 方法</title><p>回顾性收集研究对象的一般资料及CD4<sup>+</sup> T细胞绝对计数降低(&lt;544 cells/μl)，(正常值范围544~1212 cells/μl)时同期的实验室检查结果，包括24小时尿蛋白定量(尿蛋白≥0.5 g)、肌酐、C反应蛋白(C-reactive protein, CRP)、血沉(erythrocyte sedimentation rate, ESR)、血常规(complete blood count, CBC)，抗核抗体(ANA)、ENA酶谱、血清补体C3、补体C4；收集患者查出CD4<sup>+</sup> T细胞计数降低前1周、1月内激素、免疫抑制剂、免疫增强剂的应用情况。</p></sec><sec id="s4_3"><title>2.3. 统计学方法</title><p>采用SPSS 25.0统计软件进行处理。符合正态分布的计量资料采用均数&#177;标准差 ( x &#175; &#177; s ) 表示，非正态分布数据采用中位数(四分位数) [M(Q1, Q3)]表示，计数资料用百分比(%)表示。计量资料两组间比较采用t检验或Mann-Whitney U检验，三组间比较采用单因素方差分析；计数资料比较采用χ<sup>2</sup>检验；相关分析采用Spearman相关性分析。以P &lt; 0.05认为有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 人口学资料</title><p>本研究共纳入LN患者169例，其中病情稳定组92例，女性89例，男性3例，年龄19~67岁，平均(49.61 &#177; 17.83)岁，平均病程(22.61 &#177; 12.86)；病情活动组患者77例，女性75例，男性2例，年龄18~69岁，平均(40.55 &#177; 12.27)岁，平均病程(29.45 &#177; 11.43)。对照组患者64例，女性62例，男性2例，年龄20~57岁，平均(37.69 &#177; 12.75)岁，平均病程(20.78 &#177; 11.27)。三组患者年龄、性别、病程之间无统计学差异(P &gt; 0.05)，结果见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The data of sex, age and course of disease of three group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >对照组(n = 64)</th><th align="center" valign="middle" >病情稳定组(n = 92)</th><th align="center" valign="middle" >病情活动组(n = 77)</th><th align="center" valign="middle" >统计量</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >女性例数(%)</td><td align="center" valign="middle" >62 (96.87)</td><td align="center" valign="middle" >89 (96.73)</td><td align="center" valign="middle" >75 (97.40)</td><td align="center" valign="middle" >χ<sup>2</sup> = 0.068</td><td align="center" valign="middle" >0.967</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >37.69 &#177; 12.75</td><td align="center" valign="middle" >49.61 &#177; 17.83</td><td align="center" valign="middle" >40.55 &#177; 12.27</td><td align="center" valign="middle" >F = 2.738</td><td align="center" valign="middle" >0.511</td></tr><tr><td align="center" valign="middle" >病程(年)</td><td align="center" valign="middle" >20.78 &#177; 11.27</td><td align="center" valign="middle" >22.61 &#177; 12.86</td><td align="center" valign="middle" >29.45 &#177; 11.43</td><td align="center" valign="middle" >F = 1.261</td><td align="center" valign="middle" >0.492</td></tr></tbody></table></table-wrap><p>表1. 三组研究对象性别、年龄、病程资料分析</p></sec><sec id="s5_2"><title>3.2. 研究对象临床用药的比较</title><p>为除外药物因素对CD4<sup>+</sup> T细胞水平的影响，同时收集病情稳定组及病情活动组CD4<sup>+</sup> T细胞计数降低前1周、1月的临床用药情况。结果示上述2组患者在强的松(PDN)(按照激素换算标准，统一转换为强的松剂量)、吗替麦考酚酯(MMF)、环磷酰胺(CTX)、硫酸羟氯喹(HQ)、环孢素(CsA)、他克莫司(TAC)用药剂量之间无统计学差异(P &gt; 0.05)结果见表上述患者均无免疫增强剂的使用。结果见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of clinical medications between stable group and active grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >CD4<sup>+</sup> T细胞计数 降低前1周用药</th><th align="center" valign="middle"  rowspan="2"  >t</th><th align="center" valign="middle"  rowspan="2"  >P</th><th align="center" valign="middle"  colspan="2"  >CD4<sup>+ </sup>T细胞计数 降低前1月用药</th><th align="center" valign="middle"  rowspan="2"  >t</th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >病情稳定组 (n = 92)</td><td align="center" valign="middle" >病情活动组 (n = 77)</td><td align="center" valign="middle" >病情稳定组 (n = 92)</td><td align="center" valign="middle" >病情活动组 (n = 77)</td></tr><tr><td align="center" valign="middle" >PDN (mg/kg/d)</td><td align="center" valign="middle" >0.405 &#177; 0.033</td><td align="center" valign="middle" >0.467 &#177; 0.063</td><td align="center" valign="middle" >−2.063</td><td align="center" valign="middle" >0.426</td><td align="center" valign="middle" >0.502 &#177; 0.064</td><td align="center" valign="middle" >0.621 &#177; 0.086</td><td align="center" valign="middle" >−1.130</td><td align="center" valign="middle" >0.262</td></tr><tr><td align="center" valign="middle" >MMF (g/kg/d)</td><td align="center" valign="middle" >0.035 &#177; 0.002</td><td align="center" valign="middle" >0.013 &#177; 0.049</td><td align="center" valign="middle" >1.819</td><td align="center" valign="middle" >0.069</td><td align="center" valign="middle" >0.003 &#177; 0.002</td><td align="center" valign="middle" >0.076 &#177; 0.039</td><td align="center" valign="middle" >−0.943</td><td align="center" valign="middle" >0.346</td></tr><tr><td align="center" valign="middle" >CTX (g/kg/d)</td><td align="center" valign="middle" >0.198 &#177; 0.106</td><td align="center" valign="middle" >0.124 &#177; 0.071</td><td align="center" valign="middle" >0.644</td><td align="center" valign="middle" >0.519</td><td align="center" valign="middle" >0.249 &#177; 0.114</td><td align="center" valign="middle" >0.088 &#177; 0.068</td><td align="center" valign="middle" >0.968</td><td align="center" valign="middle" >0.333</td></tr><tr><td align="center" valign="middle" >HQ (g/kg/d)</td><td align="center" valign="middle" >0.001 &#177; 0.000</td><td align="center" valign="middle" >0.002 &#177; 0.000</td><td align="center" valign="middle" >−2.972</td><td align="center" valign="middle" >0.053</td><td align="center" valign="middle" >0.006 &#177; 0.003</td><td align="center" valign="middle" >0.000 &#177; 0.000</td><td align="center" valign="middle" >1.647</td><td align="center" valign="middle" >0.099</td></tr><tr><td align="center" valign="middle" >CsA (mg/kg/d)</td><td align="center" valign="middle" >0.837 &#177; 0.048</td><td align="center" valign="middle" >0.941 &#177; 0.068</td><td align="center" valign="middle" >−0.751</td><td align="center" valign="middle" >0.453</td><td align="center" valign="middle" >0.178 &#177; 0.012</td><td align="center" valign="middle" >0.100 &#177; 0.094</td><td align="center" valign="middle" >0.261</td><td align="center" valign="middle" >0.794</td></tr><tr><td align="center" valign="middle" >TAC (g/kg/d)</td><td align="center" valign="middle" >0.002 &#177; 0.001</td><td align="center" valign="middle" >0.095 &#177; 0.056</td><td align="center" valign="middle" >−0.038</td><td align="center" valign="middle" >0.969</td><td align="center" valign="middle" >0.012 &#177; 0.000</td><td align="center" valign="middle" >0.019 &#177; 0.013</td><td align="center" valign="middle" >−1.262</td><td align="center" valign="middle" >0.207</td></tr></tbody></table></table-wrap><p>表2. 病情稳定组和病情活动组研究对象临床用药的比较</p></sec><sec id="s5_3"><title>3.3. 三组研究对象之间实验室检查资料的比较</title><p>LN病情活动组患者的白细胞计数、中性粒细胞计数、淋巴细胞计、红细胞计数、血红蛋白计数、血小板计数、补体C4，补体C3计数平均值均低于病情稳定组，其中淋巴细胞计数、血红蛋白计数、血小板计数、补体C3计数在组间具有统计学差异(P &lt; 0.05)；24小时尿蛋白定量、肌酐、ESR、CRP、补体C4计数平均值高于病情稳定组，其中24小时蛋白尿定量、CRP 在组间具有统计学差异(P &lt; 0.05)，结果见表3。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of laboratory index of the stable group and active grou</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >病情稳定组(n = 92)</th><th align="center" valign="middle" >病情活动组(n = 77)</th><th align="center" valign="middle" >Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >24小时尿蛋白定量(g/d)</td><td align="center" valign="middle" >2.12 (1.43, 4.00)</td><td align="center" valign="middle" >3.51 (1.99, 5.05)</td><td align="center" valign="middle" >−1.002</td><td align="center" valign="middle" >0.026<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" >肌酐(umol/L)</td><td align="center" valign="middle" >72.55 (63.52, 88.20)</td><td align="center" valign="middle" >79.20 (64.60, 96.00)</td><td align="center" valign="middle" >−0.839</td><td align="center" valign="middle" >0.253</td></tr><tr><td align="center" valign="middle" >白细胞计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >5.60 (3.65, 7.49)</td><td align="center" valign="middle" >4.13 (3.34, 7.45)</td><td align="center" valign="middle" >−1.287</td><td align="center" valign="middle" >0.217</td></tr><tr><td align="center" valign="middle" >中性粒细胞计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >4.49 (2.53, 6.17)</td><td align="center" valign="middle" >3.35 (2.17, 5.64)</td><td align="center" valign="middle" >−1.576</td><td align="center" valign="middle" >0.108</td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.95 (0.77, 1.24)</td><td align="center" valign="middle" >0.59 (0.49, 1.24)</td><td align="center" valign="middle" >−0.834</td><td align="center" valign="middle" >0.047<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" >红细胞计数(*10<sup>12</sup>/L)</td><td align="center" valign="middle" >3.93 (3.47, 4.26)</td><td align="center" valign="middle" >3.47 (3.03, 4.12)</td><td align="center" valign="middle" >−0.372</td><td align="center" valign="middle" >0.076</td></tr><tr><td align="center" valign="middle" >血红蛋白计数(g/L)</td><td align="center" valign="middle" >113.00 (101.00, 124.00)</td><td align="center" valign="middle" >97 (81.00, 114.00)</td><td align="center" valign="middle" >−3.676</td><td align="center" valign="middle" >0.040<sup>Δ</sup></td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >血小板计数(*10<sup>9</sup>/L)</th><th align="center" valign="middle" >221.50 (113.25, 269.25)</th><th align="center" valign="middle" >121.00 (115.00, 209.00)</th><th align="center" valign="middle" >−0.861</th><th align="center" valign="middle" >0.031<sup>Δ</sup></th></tr></thead><tr><td align="center" valign="middle" >ESR (mm/60 min)</td><td align="center" valign="middle" >19.23 (9.78, 38.55)</td><td align="center" valign="middle" >30.20 (15.00, 62.00)</td><td align="center" valign="middle" >−1.804</td><td align="center" valign="middle" >0.068</td></tr><tr><td align="center" valign="middle" >CRP (mg/L)</td><td align="center" valign="middle" >2.23 (0.69, 5.18)</td><td align="center" valign="middle" >3.17 (1.50, 5.29)</td><td align="center" valign="middle" >−0.395</td><td align="center" valign="middle" >0.035<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" >C4 (g/L)</td><td align="center" valign="middle" >0.12 (0.07, 0.21)</td><td align="center" valign="middle" >0.09 (0.07, 0.26)</td><td align="center" valign="middle" >−1.223</td><td align="center" valign="middle" >0.732</td></tr><tr><td align="center" valign="middle" >C3 (g/L)</td><td align="center" valign="middle" >0.62 (0.46, 0.85)</td><td align="center" valign="middle" >0.41 (0.33 ,0.56)</td><td align="center" valign="middle" >−3.767</td><td align="center" valign="middle" >0.003<sup>ΔΔ</sup></td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 病情稳定组和病情活动组研究对象实验室指标的比较</p><p>注：病情稳定组与病情活动组比较，<sup>Δ</sup>P &lt; 0.05，<sup>ΔΔ</sup>P &lt; 0.01。</p></sec><sec id="s5_4"><title>3.4. 三组研究对象之间CD4<sup>+</sup> T细胞计数的比较</title><p>病情活动组(SLEDAI ≥ 10) CD4<sup>+</sup> T细胞计数(227.46 &#177; 104.34) cells/μl低于病情稳定组(SLEDAI &lt; 10) (348.91 &#177; 98.22) cells/μl和对照组(378.88 &#177; 169.61) cells/μl，组间差异具有统计学意义(P &lt; 0.01)，病情稳定组和对照组CD4<sup>+</sup> T细胞计数的组间差异无统计学意义(P &gt; 0.05)结果见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of serum CD4+ T cell count (cells/ml) between three group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >CD4<sup>+</sup> T细胞计数 ( x &#175; &#177; s )</th><th align="center" valign="middle" >统计量</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >对照组(n = 64)</td><td align="center" valign="middle" >378.88 &#177; 169.61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病情稳定组(n = 92)</td><td align="center" valign="middle" >348.91 &#177; 98.22</td><td align="center" valign="middle" >F = 9.052</td><td align="center" valign="middle" >0.000<sup>D</sup></td></tr><tr><td align="center" valign="middle" >病情活动组(n = 77)</td><td align="center" valign="middle" >227.46 &#177; 104.34</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 三组研究对象CD4<sup>+</sup> T细胞计数的比较</p><p>注：三组研究对象CD4<sup>+</sup> T细胞计数行组间比较，<sup>D</sup>P &lt; 0.01。</p></sec><sec id="s5_5"><title>3.5. 三组CD4<sup>+</sup> T细胞计数与SLEDAI评分、实验室检查间的相关性分析</title><p>对照组、病情稳定组和病情活动组CD4<sup>+</sup> T细胞计数与 SLEDAI评分呈负相关(r = −0.445, P = 0.039; r = −0.419, P = 0.022; r = −0.673, P = 0.001)，结果见表5。病情稳定组与病情活动组CD4<sup>+</sup> T细胞计数与24小时蛋白尿定量负相关(r = −0.544, P = 0.041; r = −0.629, P = 0.032)，与CRP呈负相关(r = −0.546, P = 0.047; r = −0.639, P = 0.000)；与血小板计数呈正相关(r = 0.324, P = 0.041; r = 0.491, P = 0.033)，与淋巴细胞计数呈正相关(r = 0.454, P = 0.001; r = 0.671, P = 0.000)，与补体C3呈正相关(r = 0.412, P = 0.048; r = 0.536, P = 0.023)，与肌酐、白细胞计数、中性粒细胞计数、血沉(ESR)、补体C4呈现相关性，但无统计学意义(P &gt; 0.05)，结果见表6。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Correlation analysis between CD4+ T cells count (cells/ml) and SLEDAI scores in three group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >CD4<sup>+</sup> T细胞计数 ( x &#175; &#177; s )</th><th align="center" valign="middle" >SLEDAI评分</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >对照组(n = 64)</td><td align="center" valign="middle" >378.88 &#177; 169.61</td><td align="center" valign="middle" >3.00 (2.00, 4.00)</td><td align="center" valign="middle" >−0.445</td><td align="center" valign="middle" >0.038<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" >病情稳定组(n = 92)</td><td align="center" valign="middle" >348.91 &#177; 98.22</td><td align="center" valign="middle" >7.00 (5.00, 8.00)</td><td align="center" valign="middle" >−0.419</td><td align="center" valign="middle" >0.022<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" >病情活动组(n = 77)</td><td align="center" valign="middle" >227.46 &#177; 104.34</td><td align="center" valign="middle" >13.00 (10.00, 14.00)</td><td align="center" valign="middle" >−0.673</td><td align="center" valign="middle" >0.001<sup>ΔΔ</sup></td></tr></tbody></table></table-wrap><p>表5. 三组研究对象CD4<sup>+</sup> T细胞计数与SLEDAI评分相关性分析</p><p>注：三组CD4<sup>+</sup> T细胞计数与SLEDAI评分比较，<sup>Δ</sup>P &lt; 0.05，<sup>ΔΔ</sup>P &lt; 0.01。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Correlation analysis between CD4+ T cell count and laboratory index in stable group and activity grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle"  colspan="4"  >CD4<sup>+ </sup>T细胞计数</th><th align="center" valign="middle"  colspan="4"  >SLEDAI评分</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >病情稳定组(n = 92)</td><td align="center" valign="middle"  colspan="2"  >病情活动组(n = 77)</td><td align="center" valign="middle"  colspan="2"  >病情稳定组(n = 92)</td><td align="center" valign="middle"  colspan="2"  >病情活动组(n = 77)</td></tr><tr><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >r</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle"  colspan="2"  >24小时尿蛋白定量(g)</td><td align="center" valign="middle" >−0.544</td><td align="center" valign="middle" >0.041<sup>Δ</sup></td><td align="center" valign="middle" >−0.629</td><td align="center" valign="middle" >0.032<sup>Δ</sup></td><td align="center" valign="middle" >0.275</td><td align="center" valign="middle" >0.038<sup>Δ</sup></td><td align="center" valign="middle" >0.511</td><td align="center" valign="middle" >0.001<sup>ΔΔ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >肌酐(umol/L)</td><td align="center" valign="middle" >−0.288</td><td align="center" valign="middle" >0.267</td><td align="center" valign="middle" >−0.259</td><td align="center" valign="middle" >0.419</td><td align="center" valign="middle" >−0.219</td><td align="center" valign="middle" >0.332</td><td align="center" valign="middle" >−0.075</td><td align="center" valign="middle" >0.627</td></tr><tr><td align="center" valign="middle"  colspan="2"  >白细胞计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.273</td><td align="center" valign="middle" >0.084</td><td align="center" valign="middle" >0.190</td><td align="center" valign="middle" >0.337</td><td align="center" valign="middle" >−0.063</td><td align="center" valign="middle" >0.738</td><td align="center" valign="middle" >−0.345</td><td align="center" valign="middle" >0.052</td></tr><tr><td align="center" valign="middle"  colspan="2"  >中性粒细胞计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.892</td><td align="center" valign="middle" >0.224</td><td align="center" valign="middle" >0.109</td><td align="center" valign="middle" >0.782</td><td align="center" valign="middle" >−0.046</td><td align="center" valign="middle" >0.587</td><td align="center" valign="middle" >−0.206</td><td align="center" valign="middle" >0.277</td></tr><tr><td align="center" valign="middle"  colspan="2"  >淋巴细胞(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.454</td><td align="center" valign="middle" >0.001<sup>ΔΔ</sup></td><td align="center" valign="middle" >0.671</td><td align="center" valign="middle" >0.000<sup>ΔΔ</sup></td><td align="center" valign="middle" >−0.349</td><td align="center" valign="middle" >0.042<sup>Δ</sup></td><td align="center" valign="middle" >−0.416</td><td align="center" valign="middle" >0.025<sup>Δ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >红细胞计数(*10<sup>12</sup>/L)</td><td align="center" valign="middle" >−0.312</td><td align="center" valign="middle" >0.354</td><td align="center" valign="middle" >−0.102</td><td align="center" valign="middle" >0.668</td><td align="center" valign="middle" >0.301</td><td align="center" valign="middle" >0.246</td><td align="center" valign="middle" >0.179</td><td align="center" valign="middle" >0.581</td></tr><tr><td align="center" valign="middle"  colspan="2"  >血红蛋白计数(g/L)</td><td align="center" valign="middle" >0.215</td><td align="center" valign="middle" >0.159</td><td align="center" valign="middle" >0.142</td><td align="center" valign="middle" >0.376</td><td align="center" valign="middle" >−0.321</td><td align="center" valign="middle" >0.012<sup>Δ</sup></td><td align="center" valign="middle" >−0.498</td><td align="center" valign="middle" >0.036<sup>Δ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >血小板计数(*10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.324</td><td align="center" valign="middle" >0.041<sup>Δ</sup></td><td align="center" valign="middle" >0.491</td><td align="center" valign="middle" >0.033<sup>Δ</sup></td><td align="center" valign="middle" >−0.332</td><td align="center" valign="middle" >0.036<sup>Δ</sup></td><td align="center" valign="middle" >−0.485</td><td align="center" valign="middle" >0.040<sup>Δ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >ESR (mm/60 min)</td><td align="center" valign="middle" >−0.112</td><td align="center" valign="middle" >0.785</td><td align="center" valign="middle" >−0.357</td><td align="center" valign="middle" >0.168</td><td align="center" valign="middle" >0.398</td><td align="center" valign="middle" >0.019<sup>Δ</sup></td><td align="center" valign="middle" >0.360</td><td align="center" valign="middle" >0.036<sup>Δ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >CRP (mg/L)</td><td align="center" valign="middle" >−0.546</td><td align="center" valign="middle" >0.047<sup>Δ</sup></td><td align="center" valign="middle" >−0.639</td><td align="center" valign="middle" >0.000<sup>ΔΔ</sup></td><td align="center" valign="middle" >0.474</td><td align="center" valign="middle" >0.029<sup>Δ</sup></td><td align="center" valign="middle" >0.528</td><td align="center" valign="middle" >0.002<sup>ΔΔ</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >C4 (g/L)</td><td align="center" valign="middle" >0.289</td><td align="center" valign="middle" >0.513</td><td align="center" valign="middle" >0.214</td><td align="center" valign="middle" >0.061</td><td align="center" valign="middle" >−0.259</td><td align="center" valign="middle" >0.107</td><td align="center" valign="middle" >0.331</td><td align="center" valign="middle" >0.274</td></tr><tr><td align="center" valign="middle"  colspan="2"  >C3 (g/L)</td><td align="center" valign="middle" >0.412</td><td align="center" valign="middle" >0.048<sup>Δ</sup></td><td align="center" valign="middle" >0.536</td><td align="center" valign="middle" >0.023<sup>ΔΔ</sup></td><td align="center" valign="middle" >−0.512</td><td align="center" valign="middle" >0.040<sup>Δ</sup></td><td align="center" valign="middle" >−0.597</td><td align="center" valign="middle" >0.011<sup>Δ</sup></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表6. 病情稳定组与病情活动组CD4<sup>+</sup> T细胞计数与实验室指标的相关性分析</p><p>注：病情稳定组与病情活动组比较，<sup>Δ</sup>P &lt; 0.05，<sup>ΔΔ</sup>P &lt; 0.01。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>目前认为LN是由遗传、基因、环境、激素等多种因素共同导致的异常免疫性炎症反应 [<xref ref-type="bibr" rid="hanspub.36158-ref5">5</xref>]。机体因免疫耐受障碍，引起免疫失衡，造成核自身抗原从免疫无能状态活化，诱导自身抗体形成原位免疫复合物沉积于肾脏系膜内、基底膜或血管内皮、上皮等部位，同时在异常激活的细胞因子、补体等成分共同作用下，导致肾脏功能损伤 [<xref ref-type="bibr" rid="hanspub.36158-ref6">6</xref>]。CD4<sup>+</sup> T细胞则是重要的免疫细胞亚群。免疫激活时，机体内初始CD4<sup>+</sup> T细胞可因免疫微环境的差异进行分化，其可分化为Thl、Th2、Thl7、Th9、Th22等不同效应T细胞，上述细胞分泌不同细胞因子等免疫物质，协同发挥免疫作用，参与体内的细胞免疫、体液免疫，及病原体感染等病变。已有研究表明CD4<sup>+</sup> T细胞与LN发病及疾病进展有着紧密的联系 [<xref ref-type="bibr" rid="hanspub.36158-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36158-ref8">8</xref>]，但目前研究多关注不同CD4<sup>+</sup> T效应细胞在LN致病机制中的作用，关于其绝对计数与疾病活动度是否相关目前暂无确切定论。本研究对LN患者的CD4<sup>+</sup> T细胞计数与疾病活动度及实验室指标进行相关性分析。结果表明，疾病活动期及稳定期时CD4<sup>+</sup> T细胞计数平均数值低于对照组，疾病活动组CD4<sup>+</sup> T细胞绝对计数明显低于稳定组，提示CD4<sup>+</sup> T细胞计数与LN患者疾病活动有密切联系。国内外已有研究结果表明：SLE患者处于疾病活动期时，相较于正常对照组及低活动组而言，CD4<sup>+</sup> T细胞异常凋亡明显增加，其外周血中数目明显减少，造成CD4<sup>+</sup>/CD8<sup>+</sup>失衡，影响细胞及体液免疫 [<xref ref-type="bibr" rid="hanspub.36158-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.36158-ref10">10</xref>]。近年来也有研究发现，LN患者外周血中淋巴细胞计数的减少与疾病活动评分具有相关性 [<xref ref-type="bibr" rid="hanspub.36158-ref11">11</xref>]，这与本研究得出的CD4<sup>+</sup> T细胞计数与SLEDAI评分成明显负相关的结果一致。其机理可能为LN疾病活动期时，因自身免疫耐受障碍使得T细胞亚群比例调控失衡，造成以Th2细胞群为主的免疫网络异常活跃，分泌IL-6、IL-10等细胞因子刺激B细胞优势发育并高活性增殖分化，B细胞成熟后分泌大量自身抗体，导致肾脏病变。同时因细胞因子异常分泌，破坏T细胞正常的发育分化进程，淋巴细胞凋亡破坏增加，最终导致CD4<sup>+</sup> T细胞比例显著骤减。再者，蛋白尿水平、血红蛋白降低、血小板减少、补体降低等表现同样也是LN疾病活动度的评判标准 [<xref ref-type="bibr" rid="hanspub.36158-ref12">12</xref>]。本研究中，病情稳定组与病情活动组CD4<sup>+</sup> T细胞计数与24小时蛋白尿水平、血红蛋白、血小板、补体C3呈现出相关性，结果与刘丹等人 [<xref ref-type="bibr" rid="hanspub.36158-ref13">13</xref>] 文献报道相符。因24小时蛋白尿水平、血红蛋白、血小板、补体C3等指标均与狼疮的疾病活动度有关，CD4<sup>+</sup> T细胞计数与以上指标的相关性也提示了其与疾病活动度的相关性。</p><p>综上所述，CD4<sup>+</sup> T细胞作为淋巴细胞主要亚群，在LN疾病的发生发展中有着重要作用。本研究表明疾病活动期及稳定期时CD4<sup>+</sup> T细胞计数平均数值低于对照组，疾病活动组CD4<sup>+</sup> T细胞计数明显低于稳定组，病情稳定组与病情活动组CD4<sup>+</sup> T细胞计数与24小时蛋白尿水平负相关，提示CD4<sup>+</sup> T细胞计数与LN患者疾病活动有密切联系，并且目前在临床中可通过流式细胞仪测得CD4<sup>+</sup> T细胞亚群占外周血中淋巴细胞数量的百分比，进而测得CD4<sup>+</sup> T细胞的计数，相较于淋巴细胞亚群的整体检测更为简便且快捷。可考虑通过监测CD4<sup>+</sup> T细胞计数的动态改变判断LN的病情活动指导临床治疗。</p></sec><sec id="s7"><title>文章引用</title><p>张媛媛,董 静,马焕焕,王丽芹,赵 磊,潘 琳,钟艳艳. CD4<sup>+</sup> T淋巴细胞计数与狼疮肾炎疾病活动度的相关性研究Correlation Analysis of CD4<sup>+</sup> T Cell Count with Disease Activity in Patients with Lupus Nephritis[J]. 临床医学进展, 2020, 10(06): 1004-1010. https://doi.org/10.12677/ACM.2020.106152</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36158-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Melderis, S., Wiech, T., Iking-Konert, C. and Steinmetz, O.M. (2018) Lupusnephritis. Zeitschrift Für Rheumatologie, 77, 1-16. &lt;br&gt;https://doi.org/10.1007/s00393-018-0496-4</mixed-citation></ref><ref id="hanspub.36158-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mesquita Jr., D., Kirsztajn, G.M., Franco, M.F., et al. (2017) CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis: An Imbalance towards a Predominant Th1 Response? Clinical &amp; Experimental Immunology, 191, 50-59. &lt;br&gt;https://doi.org/10.1111/cei.13050</mixed-citation></ref><ref id="hanspub.36158-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bombardier, C., Gladman, D.D., Urowitz, M.B., et al. (1992) Derivation of the Sledai. A Disease Activity Index for Lupus Patients. Arthritis and Rheumatology, 35, 630-640. &lt;br&gt;https://doi.org/10.1002/art.1780350606</mixed-citation></ref><ref id="hanspub.36158-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Petri, M., Orbai, A.M., Alarcón, G.S., et al. (2012) Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology, 64, 2677-2686.  
&lt;br&gt;https://doi.org/10.1002/art.34473</mixed-citation></ref><ref id="hanspub.36158-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yu, F., Haas, M., Glassock, R., et al. (2017) Redefining Lupus Nephritis: Clinical Implications of Pathophysiologic Subtypes. Nature Reviews Nephrology, 13, 483-495. &lt;br&gt;https://doi.org/10.1038/nrneph.2017.85</mixed-citation></ref><ref id="hanspub.36158-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Xu, J., Zhang, X., et al. (2017) Tubular Basement Membrane Immune Complex Deposition Is Associated with Activity and Progression of Lupus Nephritis: A Large Multicenter Chinese Study. Lupus, 27, 545-555.  
&lt;br&gt;https://doi.org/10.1177/0961203317732407</mixed-citation></ref><ref id="hanspub.36158-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘亚. CD4+ T细胞亚群在狼疮肾炎中的免疫病理作用研究进展[J]. 中国医师杂志, 2015, 17(7): 1115-1117.</mixed-citation></ref><ref id="hanspub.36158-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">岳利环, 林进. CD4+ T淋巴细胞亚群在自身免疫性疾病中的研究进展[J]. 中华微生物学和免疫学杂志, 2012, 32(5): 477-480.</mixed-citation></ref><ref id="hanspub.36158-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X.L., Qiu, C.L., Wu, X.M., et al. (2010) Study on the Apoptosis of T Lymphocytes of Peripheral Blood in Systemic Lupus Erythematosus (SLE) and the Correlated Pathogenesis. Chinese Journal of Immunology, 2, 48-353+359.</mixed-citation></ref><ref id="hanspub.36158-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Katsuyama, T., Tsokos, G.C. and Moulton, V.R. (2018) Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Frontiers in Immunology, 9, 1088. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.01088</mixed-citation></ref><ref id="hanspub.36158-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Samia, F., Mohamed, E. and Azza, A. (2014) Lymphopenia and Systemic Lupus Erythematosus, a Preliminary Study: Correlation with Clinical Manifestations, Disease Activity and Damage Indices. The Egyptian Rheumatologist, 36, 125-130. &lt;br&gt;https://doi.org/10.1016/j.ejr.2014.01.005</mixed-citation></ref><ref id="hanspub.36158-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zucchi, D., Elefante, E., Calabresi, E., et al. (2019) One Year in Review 2019: Systemic Lupus Erythematosus. Clinical and Experimental Rheumatology, 37, 715-722.</mixed-citation></ref><ref id="hanspub.36158-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">刘丹, 张舒, 雷婷, 等. 血液相关指标与系统性红斑狼疮活动性分析[J]. 标记免疫分析与临床, 2019(5): 741-744.</mixed-citation></ref></ref-list></back></article>